Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CATARTIC: Preoperative Capecitabine + Temozolomide in Rectal Cancer
NCT05136326Phase 2Recruiting
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Dec 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in rectal cancer, sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Pathological Complete Response Rate at 24 months. Started Dec 2021; status: recruiting.
02
Drugs
temozolomide
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05136326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05136326.